By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Oculus Innovative Sciences, Inc. 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


SEARCH JOBS

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

Key Statistics


Email: hr@oculusis.com
Ownership: Public

Web Site: Oculus Innovative Sciences, Inc.
Employees:
Symbol: OCLS
 









Company News
Oculus Innovative Sciences, Inc. (OCLS) Announces Sale Of 350,000 Shares Of Ruthigen Stock For $962,500 In Non-Dilutive Funding 3/16/2015 7:25:18 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces New Animal Healthcare Division And Launch Of Microcynah Advanced All-Animal Healthcare Products 2/26/2015 8:00:30 AM
Oculus Innovative Sciences, Inc. (OCLS) Reports Financial Results For The Third Quarter Of Fiscal Year 2015 2/13/2015 7:54:33 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal Third Quarter 2015 Financial Results And Conference Call 1/29/2015 8:03:44 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Closing Of $6.3 Million Underwritten Public Offering 1/27/2015 7:46:10 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Pricing Of Upsized $6.3 Million Underwritten Public Offering 1/21/2015 7:27:12 AM
Oculus Innovative Sciences, Inc. (OCLS) Enters Into Agreement To Sell Ruthigen Shares For $5.5 Million In Event Of Ruthigen Merger 1/12/2015 7:02:10 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces New Dermatology Division, IntraDerm Pharmaceuticals 1/7/2015 10:19:43 AM
Oculus Innovative Sciences, Inc. (OCLS) Reports Financial Results For The Second Quarter Of Fiscal Year 2015 11/14/2014 10:34:41 AM
Oculus Innovative Sciences, Inc. (OCLS) Commercializes Microcyn®-Based Solution And Hydrogel For Treatment Of Mild-To-Moderate Acne In Europe 11/11/2014 10:20:04 AM
12345678910...
//-->